{"id":"aoc-1001-del-desiran","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5756119","moleculeType":null,"molecularWeight":"502.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Del-desiran is designed to selectively deliver antisense oligonucleotides to target tissues using Avidity's AOC (Antisense Oligonucleotide Conjugate) platform. The conjugate binds to a tissue-specific receptor to facilitate cellular uptake and subsequent knockdown of the target gene expression, reducing production of the pathogenic protein.","oneSentence":"AOC 1001 is an antisense oligonucleotide conjugate that targets and reduces expression of a disease-causing gene through a tissue-directed delivery approach.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:00.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Desmin-related myopathy (DRM)"}]},"trialDetails":[{"nctId":"NCT07008469","phase":"PHASE3","title":"Global Open-Label Extension Study of Del-desiran for the Treatment of DM1","status":"ENROLLING_BY_INVITATION","sponsor":"Avidity Biosciences, Inc.","startDate":"2025-07-25","conditions":"Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy","enrollment":230},{"nctId":"NCT06411288","phase":"PHASE3","title":"Global Study of Del-desiran for the Treatment of DM1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avidity Biosciences, Inc.","startDate":"2024-05-30","conditions":"DM1, Myotonic Dystrophy, Myotonic Dystrophy 1","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AOC 1001 (del-desiran)","genericName":"AOC 1001 (del-desiran)","companyName":"Avidity Biosciences, Inc.","companyId":"avidity-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AOC 1001 is an antisense oligonucleotide conjugate that targets and reduces expression of a disease-causing gene through a tissue-directed delivery approach. Used for Desmin-related myopathy (DRM).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}